{"abstract": "Allergan, the target of a $52 billion hostile bid, is linking stock and option grants to lofty profit goals. It is a bold tactic that should become a norm in M.&A., contends Robert Cyran of Reuters Breakingviews.", "web_url": "https://dealbook.nytimes.com/2014/07/24/allergans-bosses-put-money-on-where-their-mouths-are/", "snippet": "Allergan, the target of a $52 billion hostile bid, is linking stock and option grants to lofty profit goals. It is a bold tactic that should become a norm in M.&A., contends Robert Cyran of Reuters Breakingviews.", "lead_paragraph": "Allergan\u2018s bosses have put money where their mouths are.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-articleLarge.jpg", "height": 444, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 444}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-jumbo.jpg", "height": 757, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-superJumbo.jpg", "height": 1036, "width": 1401, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Botox Maker\u2019s Bosses Put Money Where Their Mouths Are", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Executive Compensation", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "rank": 7, "major": "N"}], "pub_date": "2014-07-24T16:04:36+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/7c1279c1-aa77-511a-8b4f-49a8ae1e1532", "word_count": 385, "uri": "nyt://article/7c1279c1-aa77-511a-8b4f-49a8ae1e1532"}